TY  - JOUR
AU  - Poorebrahim, Mansour
AU  - Quiros-Fernandez, Isaac
AU  - Fakhr, Elham
AU  - Cid-Arregui, Angel
TI  - Generation of CAR-T cells using lentiviral vectors.
JO  - Methods in cell biology
VL  - 167
SN  - 0091-679x
CY  - New York, NY [u.a.]
PB  - Elsevier
M1  - DKFZ-2022-00301
SP  - 39-69
PY  - 2022
N1  - #EA:D122#LA:D122#
AB  - Cancer immunotherapy is nowadays largely focused on the development of therapeutic antibodies and chimeric antigen receptors (CARs). Two CARs targeting CD19 have been approved recently for the treatment of some hematological malignancies. This demonstrates the capability of engineered CAR T cells in generating effective tumor responses. Furthermore, several hundred ongoing clinical trials are exploring the feasibility of CAR-based approaches to target tumor-associated antigens in solid tumors. However, there still remain significant challenges and limitations in the design and production of CAR-modified T cells that need to be addressed, such as more effective transduction methods, expression and exhaustion issues, reliable in vitro and in vivo characterization methods, etc. Here we describe current techniques for generating CAR T cells using lentiviral vectors as well as detailed protocols for their functional characterization.
KW  - CAR-T (Other)
KW  - Cell avidity analysis (Other)
KW  - Chimeric antigen receptor (CAR) (Other)
KW  - Electroporation (Other)
KW  - Jurkat (Other)
KW  - Lentiviral vector (Other)
KW  - PBMC (Other)
KW  - Transposon system (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:35152998
DO  - DOI:10.1016/bs.mcb.2021.07.001
UR  - https://inrepo02.dkfz.de/record/178838
ER  -